This inventor holds 1 USPTO granted patent, plus 3 CIPO patents. Top assignee: Eli Lilly and Company. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Antonio Rodriguez Hergueta: Innovator in Protein Kinase Inhibitors
Introduction
Antonio Rodriguez Hergueta is a notable inventor based in Spain, recognized for his contributions to the field of medicinal chemistry. His work primarily focuses on the development of compounds that serve as protein kinase inhibitors, which are crucial in the treatment of various diseases, including cancer. Despite having no patents registered under his name, his innovative research has significant implications for therapeutic applications.
Latest Patents
Antonio's latest patents include "Macrocyclic Compounds As Protein Kinase Inhibitors" and "Tricyclic Compounds For Use As Kinase Inhibitors." The first patent provides compounds of formula I, along with pharmaceutically acceptable esters, amides, solvates, or salts thereof. These compounds are designed to inhibit specific protein or lipid kinases, such as PI3-K and mTOR, which are essential in cancer treatment. The second patent also presents compounds of formula (I) that target PIM family kinases, offering potential treatments for cancer and proliferative diseases.
Career Highlights
Throughout his career, Antonio Rodriguez Hergueta has made significant strides in the field of drug discovery and development. His research has focused on creating innovative compounds that can effectively inhibit key kinases involved in various diseases. His work is characterized by a commitment to advancing therapeutic options for patients suffering from serious health conditions.
Collaborations
Antonio has collaborated with notable colleagues, including Joaquin Pastor Fernandez and Carmen Blanco Aparicio. These partnerships have enhanced the scope and impact of his research, leading to advancements in the development of kinase inhibitors.
Conclusion
Antonio Rodriguez Hergueta is a dedicated inventor whose work in protein kinase inhibitors holds promise for the future of cancer treatment. His innovative research continues to pave the way for new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile